Intermittent Claudication – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Intermittent claudication (IC) is characterized by skeletal muscle pain in the lower extremities during exercise, resulting from insufficient oxygen delivery to meet metabolic demands. It is a prevalent manifestation of peripheral arterial disease (PAD), typically caused by atherosclerotic stenosis of arteries supplying the extremities. Pain is commonly felt in the thigh, hip, buttock, and calf muscles, induced by walking and alleviated with rest. The severity of pain often correlates with the degree of arterial stenosis. Reproducibility of muscle discomfort distinguishes intermittent claudication, with pain occurring during physical activity and subsiding after rest due to inadequate blood flow. It is frequently observed in patients with diabetes mellitus and individuals who smoke. Medical management offers effective treatment for most individuals with intermittent claudication. Therapies include cilostazol, blood pressure control, antiplatelet agents, statins, glycemic management, structured exercise programs, and smoking cessation. These interventions aim to improve blood flow, alleviate symptoms, and mitigate the progression of peripheral arterial disease.

Thelansis’s “Intermittent Claudication Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Intermittent Claudication treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Intermittent Claudication across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Intermittent Claudication Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Intermittent Claudication – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033